Centre Hospitalier Regional Universitaire de Lille and Centre National de la Recherche Scientifique have patented norbornene analogues reported to be useful for the treatment of tuberculosis.

Chugai Pharmaceutical Co. Ltd. has divulged nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NRF2) activators reported to be useful for the treatment of neurodegenerative, pulmonary and renal diseases.

Researchers from Tokyo University of Science presented the discovery and preclinical evaluation of a novel KRAS-degrading small molecule candidate being developed for the treatment of cancer.

Mansonone E is a type of plant toxin with various pharmacological properties, including antimicrobial, anti-MRSA and antitumor activities. In the current study, researchers from Sun Yat-Sen University presented the discovery of novel mansonone E analogue, MSN-8C, being developed as a potential anticancer agent.

Biocity Biopharma announced that the U.S. FDA has accepted its investigational new drug (IND) application for BC-3448, a bispecific antibody that targets the T cell marker CD3 and epidermal growth factor receptor (EGFR), bringing antitumor T cells in proximity to EGFR-expressing cells. To reduce the risk of cytokine release syndrome (CRS), a known risk of CD3-targeting antibodies, the bispecific has a higher affinity for EGFR than CD3.

Most lung adenocarcinoma tumors with EGFR mutations respond to tyrosine kinase inhibitors (TKIs, e.g., osimertinib). Accordingly, there are now >50 different FDA-approved TKIs. Still, acquired resistance remains as the major limitation preventing long-term efficacy.